THE HOLY GRAIL



Transplant immune tolerance has been called the "holy grail" of transplantation. Any therapy or intervention that could preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs would be widely welcomed. Any such therapy or intervention that could preserve or improve transplant kidney function and prevent graft rejection without the need for most or all of the currently available immunosuppression drugs would be transformational. Cellular immunotherapies such as the MDR-10X series of product candidates have the potential to improve transplant organ and transplant recipient outcomes and avert the toxic side effects associated with anti-rejection drug regimens. What has been viewed as impossible for so many years may be possible because of Medeor and MDR-10X.


Learn About MDR-10X Cellular Immunotherapy





Marcén R. Immunosuppressive drugs in kidney transplantation. Drugs 2009;69: 2227-2243.
Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351: 2715-2729.
Silkensen JR. Long-term complications in renal transplantation. J Am Soc Nephrol 2000;11: 582-588.
Engels EA, Pfeiffer RM, Fraumeni Jr JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306: 1891-1901.
Opelz G and Döhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003;4: 222-230.